- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01939418
Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
A Phase Ib Trial of Gemcitabine and Cisplatin With RAD001 in Patients With Metastatic Triple Negative Breast Cancer Proceeding to an Open Label Randomized Phase II Trial Comparing Gemcitabine/Cisplatin With or Without RAD001.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
PIK3CA active mutations are the most frequent genetic event in breast cancer, including in TNBC which presents activated PI3K/AKT signaling due to PIK3CA mutation or PTEN deficiency. TNBC cell lines having activated PI3K/AKT signaling showed a high sensitivity to PI3K/mTOR inhibitors. RAD001 is a potent mTOR complex 1 inhibitor and showed to enhance cisplatin or gemcitabine induced apoptosis by inhibiting p53 induced p21 expression.
This study consists of two parts. In a phase Ib part, investigators will explore the recommended dose of gemcitabine, cisplatin, and RAD001 combination in patients with metastatic TNBC. After completing the phase Ib part, investigators will review the data and discuss with Novartis before the start of a phase II part. In the phase II part, investigators will compare the efficacy of the gemcitabine and cisplatin with or without RAD001 in patients with metastatic TNBC.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Gyeonggido
-
Goyangsi, Gyeonggido, Korea, Republik von, 410-769
- National Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Females with histologically confirmed, metastatic or stage IV breast cancer
- ER/PgR negative or poor (Allred score ≤ 3/8) and HER2 negative breast cancer
- ECOG performance status 0-2
- Age ≥ 20 years
- Previously treated by anthracycline and taxane in adjuvant/neoadjuvant or metastatic setting
- ≤ 2 chemotherapy regimens for metastatic disease
- Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to enrolment.
- CNS metastasis is permitted if asymptomatic and not requiring treatment with steroids and is documented to be non-progressing at study entry
- Presence of measurable or evaluable disease by RECIST 1.1 criteria
- Adequate hematopoietic function: Absolute granulocyte count ≥1,500/mm3, platelet ≥100,000/mm3, hemoglobin ≥ 10g/mm3
- Adequate hepatic function: total bilirubin ≤ 1.5 x upper normal limit (UNL), AST/ALT ≤2.5 x UNL or ≤5 x UNL if presented with hepatic metastasis
- Fasting serum cholesterol ≤ 300mg/dl and fasting triglycerides ≤ 2.5 x UNL
- Adequate renal function: Serum creatinine ≤1.5mg/dL
- Patients should sign a written informed consent before study entry
- Patients with positive HBV-DNA of HBsAg at screening must initiate prophylaxis with appropriate antiviral medication at least one week prior to treatment start
Exclusion Criteria:
- Known active CNS metastasis
- Patients who received prior therapy with gemcitabine
- Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites).
- Patients with more than 3 prior chemotherapy lines for treating metastatic breast cancer.
- Patients who received prior therapy with mTOR inhibitor or PI3K inhibitor
- Known hypersensitivity to mTOR inhibitors, e.g. Sirolimus (rapamycin).
- Radiotherapy within four weeks prior to enrolment, except radiotherapy to the bone for analgesic purpose or for lytic lesions at risk of fracture. Patients must have recovered from radiotherapy toxicities prior to enrolment.
- Patients who have history of cancer other than in situ uterine cervix cancer or nonmelanotic skin cancer
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
- Active ulceration of upper gastrointestinal tract
- Other concurrent severe and/or uncontrolled conditions (e.g. uncontrolled diabetes mellitus, active untreated or uncontrolled infection, chronic obstructive or chronic restrictive pulmonary disease including dyspnea at rest from any cause) that could cause unacceptable safety risks or compromise compliance with the protocol.
- Patients with a known history of HIV seropositivity. Screening for HIV infection at baseline is not required.
- Significant symptomatic deterioration of lung function. If clinically indicated, pulmonary function tests including measures of predicted lung volumes, DLco, O2 saturation at rest on room air should be considered to exclude restrictive pulmonary disease, pneumonitis or pulmonary infiltrates.
- Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A at enrolment (rifabutin, rifampicin, clarithromycin, ketoconazole, itraconazole, voriconazole, ritonavir, telithromycin) continuously for at least 7 days during any time period in the last 2 weeks prior to enrolment
- Known hypersensitivity to protocol treatment
- Pregnant or breast feeding
- Peripheral neuropathy ≥ grade 2 (NCI CTCAE version 4.0) at randomization
- Patients unwilling to or unable to comply with the protocol
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: RAD001
gemcitabine 800mg/m2, D1 and D8 iv.
every 3 weeks.
cisplatin 30mg/m2, D1 and D8 iv.
every 3 weeks.
RAD001 5mg QD. po.
|
Afinitor 5mg qd. po.
Andere Namen:
gemcitabine 800mg/m2 iv.
D1 and D8 every 3 weeks
cisplatin 30mg/m2 iv.
D1 and D8 every 3 weeks
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
The recommended dose of the combination of gemcitabine, cisplatin and RAD001 (everolimus) in patients with metastatic triple-negative breast cancer
Zeitfenster: up to 1 year
|
phase IB part
|
up to 1 year
|
Efficacy of gemcitabine and cisplatin with or without RAD001 in patients with metastatic triple-negative breast cancer by evaluating progression free survival (PFS)
Zeitfenster: up to 5 years
|
phase II part
|
up to 5 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
The maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gemcitabine/cisplatin/RAD001
Zeitfenster: up to 1 year
|
phase Ib part
|
up to 1 year
|
number of patients with adverse events as a measure of safety and tolerability
Zeitfenster: up to 5 years
|
phase Ib and phase II
|
up to 5 years
|
objective response rate
Zeitfenster: up to 1 year
|
phase Ib and phase II
|
up to 1 year
|
Overall survival (OS)
Zeitfenster: up to 5 years
|
phase Ib and phase II
|
up to 5 years
|
check biomarkers associated with the response of RAD001: angiogenesis, metabolism, immune cells profiles
Zeitfenster: up to 5 years
|
phaseIb and phaseII
|
up to 5 years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: In Hae Park, Doctor, National Cancer Center, Korea
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Hautkrankheiten
- Neubildungen
- Neubildungen nach Standort
- Brusterkrankungen
- Neoplasien der Brust
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Enzym-Inhibitoren
- Antimetaboliten, antineoplastisch
- Antimetaboliten
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Gemcitabin
- Everolimus
Andere Studien-ID-Nummern
- NCCCTS-13-670
- 12491 (Andere Kennung: Korea Food and Drug Administration)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Metastasierter Brustkrebs
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
Klinische Studien zur RAD001
-
Children's Hospital Medical Center, CincinnatiNovartisAbgeschlossenTuberöse Sklerose | AngiolipomVereinigte Staaten
-
Novartis PharmaceuticalsAbgeschlossenMetastasiertes Nierenzellkarzinom (mRCC)Deutschland
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Children's Hospital of Philadelphia; Washington... und andere MitarbeiterAbgeschlossen
-
Novartis PharmaceuticalsAbgeschlossen
-
Novartis PharmaceuticalsAbgeschlossenLymphangioleiomyomatose (LAM) | Tuberöse Sklerose-Komplex (TSC)Vereinigte Staaten, Vereinigtes Königreich, Deutschland, Italien, Russische Föderation, Niederlande, Japan, Kanada, Polen, Frankreich, Spanien
-
Fox Chase Cancer CenterRekrutierungMetastasierter BauchspeicheldrüsenkrebsVereinigte Staaten
-
Guangdong Provincial People's HospitalNovartisUnbekanntNeuroendokrine Tumoren | Karzinoider TumorChina
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyAbgeschlossenTumore des Gehirns und des zentralen NervensystemsVereinigte Staaten, Israel, Kanada
-
Novartis PharmaceuticalsBeendetHepatozelluläres KarzinomVereinigte Staaten, Spanien, Korea, Republik von, Niederlande, Taiwan
-
Anne Beaven, MDNovartisBeendetDiffuses großzelliges B-Zell-LymphomVereinigte Staaten